indicate Thanks, joining play disease our Seres made on for We efforts pipeline. a for is our role. all important, has advancing areas microbiome developing immuno-oncology. our positive were to states target an efforts thank microbiome such has provide Carlo. data the with obtained data microbiome therapeutics clinical potential notably gastrointestinal us. immune in serious Seres' our multiple progress substantial advance central metabolic microbiome new and will excellent dysbiosis focused including diseases, pipeline, progress preclinical diseases in and R&D to as to is I today's diseases therapeutic call, most And is infectious we human and/or of that SER-XXX. address on and the believe that you On the thought the therapeutics Seres diseases, including where update compelling inflammatory
healthy array human orally-administered, natural, let's with in is spore the reside that commensal So, SER-XXX. an form biologically-sourced bacteria species gastrointestinal comprised candidate begin of wide of a drug in of tract. SER-XXX
subjects, into for human conditions germination manufacturing reach been four least advanced the transplants, patients. hardy transplants from are studies the physiologically where donor Our of microbiota Repetitive evaluated benefit spores or at and have colon in These they randomized, fecal FMPs, of placebo-controlled studies Both microbiota indicated the fecal colitis inactive process active state. and clinical preclinical would spore they that bacterial isolates until have ulcerative metabolically purifies action transform material. a XX double-blind, randomized, the announced the standard who results trial the positive to clinical Last remission their role clinical with ulcerative active and moderate SER-XXX and the supporting colitis. with placebo-controlled, therapy. mild efficacy lead ulcerative patients Phase that in colitis Ib strong a evidence ulcerative we was demonstrated. study, microbiome microbiome can multiple from of were This in of month, clinical colitis, dose shows modulation failing provide to
were As pretreatment, three a dosing arm arms weekly and treatment at and were study of study's The score vancomycin rectal objectivity seen collected included end with pretreatment. on listed a arm arm The a at measures is placebo the methods illustrated weekly arms on a arm. to stool slide statistical efficacy are pretreatment on of reader. daily slide endoscopic maximize evaluation, were to blinded assessed In recordings assigned all SER-XXX Mayo six. physician's order a bleeding, central in with evaluated modified SER-XXX were analyze Mayo a all or used on one four, SER-XXX of baseline endpoints five. based to outcomes. Total assessment, endoscopic These slide dosing subjects evaluation. intend-to-treat of The are scores subjects by endoscopy Ib vancomycin frequency, the a global Two the prespecified, treatment. dosing and Phase
second both highest all the missing failure. rates vancomycin the pretreatment in and method SER-XXX Analyses arm observed and efficacy demonstrated remission each a in was clinical scores. analyzed the as improvement study. analyzed first dose-dependent counted endoscopic data of The resulted from observed daily that approach SER-XXX of data administration The
patients a data achieved XX this XX a X or had XX% on or protocol analysis remission, seen the the slide based actually of The patients violation. achieved placebo study placebo only flare an As in arm, and seven, during in steroids, endpoint on reached remission patient while who group. of single observed this received X intend-to-treat XX%
remission patient approach patient remission clinical as counted because study, observed a However, was this protocol. the end the they at of in violated the even though the prespecified data
remission. counted initial statistically in X of now of failure. this under data other subjects this X.XXXX. in p But XX reached Now, to missing eight, slide value result Again, prespecified moving X%, significant clinical as XX% with the method, of Even zero rather compared group. study, the or modestly-sized was placebo a to XX
that statistical direct compelling similar also placebo of arms. clinical analyses. Based on response now response also were on UC. the response study. remission high effects treatment XXXX FDA's rates treatment data observed I high observed and the clinical the response endpoint endpoint, from We August discuss endpoint, not variability. endpoint regulatory In wanted in we to both Clinical of the addition rates and saw clinical differentiated to in recommends from not the magnitude primary the guidance XXX in clinical the clinical registrational is in for as clinical measures the of remission use a response drawbacks prone to subjective the a studies all latest endoscopic
mechanisms modestly-sized believe that are drugs in been colitis data As studies, to clinical very such, high interpret response action. demonstrated placebo several in Phase in particularly using II of clearly difficult We rates diverse from in response study. have trials clinical previous interpreting any UC rates ulcerative when with
the our on bleeding frequency on endoscopies zero the initiated, defined that Now, after and new prior slide new be part on or made requires recent score FDA was subscore. most modifications guidance seen implemented protocol have SER-XXX nine. of of achieved, clinical subject a clinical as both zero rectal be remission were Because subscores the one the Mayo to the were study FDA's analyses stool and based can FDA in to statistical The guidance, a remission. on the for definition guidance standards. These this a must was
FDA guidance this new the observed as remission. improvement the counted is with new were of compelling. missing and the results increased daily guidance, associated FDA the missing for analyzed SER-XXX guidance, data can efficacy remission analyzed data however, the per in using the included of When our seen is be as guidance. in data have, the improvement both data analyses study SER-XXX results slides remission significant is new results level XX case on This endoscopic rates analyzed daily highly defining the We Indeed, Interestingly, arm. endoscopic based improvement These with new statistically failure seen analyzed XX. our rates also when on FDA and clinical the under statistical remain arm clinical FDA and endpoint study failure are analyses. the significance clinical the SER-XXX both counted analyses the the when definition the in
not clinical primary under recommended response As as nor previously new the defined mentioned, is FDA guidance. endpoint a
favorable. The adverse was the in SER-XXX to as were Now, arm SER-XXX drug-related serious patients treated to there safety with very compared imbalance placebo no and the and demonstrated SER-XXX moving in no safety. SER-XXX. adverse Results associated on events tolerability profile events
to that subjects the with a placebo. line evidence also impact SER-XXX independent arm GI-related daily adverse this in of observed additional interestingly, fewer those pointing we than SER-XXX on activity. beneficial dosing represents believe an experienced And Now, treated events disease we
point If website. additional slides you on in information, to are detailed you interested I our available results are would that study the
help including coming the including could provide into SER-XXX's study, future mechanism to look SER-XXX months. SER-XXX analyses, data were forward histology these and and additional and the products, believe Ib the continue biomarkers synthetic very program. from further important Overall, our inform other fully we results. in We efforts data Phase SER-XXX XXX development detailed the pleased microbiome of with We Ib development insights could to of phase action follow-on
available Our and a often entirely mechanistic a to orally option, that SER-XXX objective that novel need provide with SER-XXX is hope new is administered is is Ulcerative not mechanistic is effective, condition for all importantly will debilitating treatments. approaches therapeutic is highly develop refractory to highly which high our a it There immunosuppressive. colitis an approach.
FDA maximizes that to intend data. to the considering optimal for now once next with a are SER-XXX. development determine the We we meet the plan steps We remaining study obtain development
program patients with C. to diff III Now, our SER-XXX moving infection. for recurrent Phase multiply
to enrolling sites continued make have progress actively and clinical We adding patients.
we and FDA emerging Seres Health efficacy trial primarily approval. In also forward microbiome as notable in and deep Phase SER-XXX Based file active Phase Phase persuasive Ib We tolerability single and therapeutic the from diff make weeks. US that safety to SER-XXX changes. Canada with infection. able driving designations a the an designed, have C. modality. also as fermentation-generated the expect pharmacodynamics rationally Seres pharmacokinetics candidate. progress multi-strain, results important the to the our it safety from drug by first-ever evaluate coming clinical SER-XXX is trial the in are in application received a expect with you, clinical study remind measured microbiome patients FDA, To first-in-human, SER-XXX both orphan continued interest III breakthrough this study, with study, evaluating in study therapeutic and obtained regulatory discussions clearance be this and has to recently and has clinical Canadian the of would dose-ranging primary on and we demonstrated also to is has that, SER-XXX sites for microbiome Ib
evaluate in XXXX. obtaining across Ib line top cohorts. early clinical also dose results will Phase the efficacy We SER-XXX anticipate trends We study
a liver diseases, clinical make programs, metabolic continue has three efforts, R&D advancing partnership the grant those antibacterial diseases stage earlier-stage million immuno-oncology. our up CARB-X preclinical to of $X.X Seres will from we and devoted inflammatory SER-XXX program. that CARB-X been novel a therapeutic our addition to approaches. to awarded in support our of to advancement In just public-private is in progress including diseases,
infections, designed data serious patients are in graft-versus-host than We stem SER-XXX, rates reduce more either developing have as microbiomes. supporting outcomes or diverse to healthier, who is both rationally transplantation. well clinical bacterial dysbiotic receive rationale gastrointestinal allogeneic as with a microbiomes The on those better with cell solid more showing of that composition organ SER-XXX patients based disease
our to support to finalize into call the we I'll study. intend a Eric financial move with to clinical the of And continue program pass of funds, now to this review will performance. the SER-XXX. We recent CARB-X composition
